1. Beck, W. T., Mueller, T., and Tanzer, L., 1979, Altered surface membrane glycoproteins in vinca alkaloid resistant human leukemic lymphoblasts, Cancer Res. 39:2070–2076.
2. Beck, W. T., Cirtain, M. C., Look, A. T., and Ashumn, R. A., 1986, Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil, Cancer Res. 46:778–784.
3. Beck, W. T., Cirtain, M. C., Danks, M. K., Felsted, R. L., Safa, A. R., Wolverton, J. S., Suttle, D. P., and Trent, J. M., 1987, Pharmacologic, molecular and cytogenetic analysis of “atypical” multidrug resistant cells, Cancer Res. 47:5455–5460.
4. Bell, D. R., Trent, J. M., Willard, H. F., Riordan, J. R., and Ling, V., 1987, Chromosomal location of human P-glycoprotein gene sequences, Cancer Genet. Cytogenet. 25:141–148.
5. Biedler, J. L., and Peterson, R. H. R., 1981, Altered plasma membrane glycoconjugatyes of Chinese hamster cells with acquired resistance to actinomycin D, daunorubicin, and vincristine, in: Molecular Actions and Targets for Cancer Chemotherapeutic Agents, (A. C. Sartorelli, L. S. Lazo, and J. R. Berlino, eds.) Academic Press, New York pp. 453–482.